150 mg fluconazole
It is indicated in the treatment of mycosis following:
Ringworm (Tinea Pedis, Tinea Corporis, Tinea Curis, Tinea Versicolor and Tinea Unguium).
Cryptococcosis (including meningitis), systemic candidiasis, mucosal, vaginal, in normal hosts or immunocompromised (AIDS, transplant recipients, patients in intensive care, patients under cytotoxic or other immunosuppressive factors).
DOSAGE AND ADMINISTRATION:
Route of administration: Oral.
Dosage: The dosage will depend on the nature and severity of the infection.
The duration of treatment depends on the clinical and mycological response, but recommended schemes are: in Cryptococcus infections, 400 mg on the first day followed by 200 to 400 mg, once a day; in case of meningitis, for at least 6 to 8 weeks. In patients with AIDS and to prevent relapse meningitis should be given 200 mg daily indefinitely.
In systemic candidiasis, the usual dose is 400 mg on the first day followed by 200 mg daily, and can be administered up to 400 mg daily. Oropharyngeal candidiasis, 100 mg once daily for 7 to 14 days. Vaginal yeast infection, it is recommended 150 mg, single dose.
For prevention in patients with cancer, we recommend 100 mg a day, while the patient is at risk for a fungal infection.
In case of ringworm (tinea), the recommended dose is 150 mg in a single dose a week for 2-4 weeks but tinea pedis may require up to six weeks.
There is no experience in children for treatment, but is recommended over 1 year and normal renal function from 1 to 2 mg / kg for superficial infections by Candida and 3 to 6 mg / kg for systemic infections by Candida or Cryptococcus. Do not exceed the maximum dose of 400 mg.
Geriatric Use: In patients where there is no evidence of renal impairment should follow the usual dosage recommendations.
In patients with renal failure depend on creatinine clearance. Greater than 50 ml / min usual dose of 11 to 50 ml / minute half-dose.
Known hypersensitivity to the drug or other compounds from the group of azoles, terfenadine and cisapride, pregnancy and lactation.
In those patients who present a significant increase in liver enzymes, the risk should be assessed against the benefits of continuing treatment with fluconazole, in histopathological studies has been found hepatic necrosis without this being attributable to it, as these patients had received other potentially hepatotoxic drugs.
RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING:
During pregnancy should be avoided the use of fluconazole, except in patients with severe or life-threatening infections in whom the benefit with the use of fluconazole exceeds the potential risk to the fetus.
Use during breastfeeding: Fluconazole achieves significant concentrations in breast milk, so it is not recommended for use during this period.
Use in children: There are limited data on the use of fluconazole in children, so it should not be used in children under 1 year.
Is well tolerated, however, there may be headache, nausea, abdominal pain, diarrhea, dyspepsia, flatulence, dizziness, seizures, alopecia, skin changes and leukopenia. Also reported rash, which in AIDS patients may be more serious.
Patients with systemic invasive fungal infections who develop rash, should be followed closely; discontinue treatment if developed bullous lesions or erythema multiforme.
Fluconazole increases the prothrombin time after the administration of warfarin in healthy men, it is recommended for monitoring patients receiving anticoagulant of the coumarin type.
It has been shown that the use of fluconazole prolongs the average life of the sulfonylureas; therefore must keep in mind that coadministration may result in hypoglycemia. Coadministration with multiple doses of hydrochlorothiazide increases plasma concentrations of fluconazole in 40% without requiring change in the dosing schedule of fluconazole. Coadministration of fluconazole and phenytoin may increase levels of the latter.
Coadministration of fluconazole and rifampicin reduced the half-life of fluconazole. Coadministration of fluconazole and theophylline clearance affects latter.
Coadministration of terfenadine with fluconazole at doses of 400 mg or more leads to increased plasma levels of terfenadine. Concomitant use with cisapride may have cardiac abnormalities. With rifabutin, tacrolimus and zidovudine noted also increase serum levels of these.
OVERDOSE OR ACCIDENTAL INGESTION:
Is recommended with symptomatic treatment with support measures and stomach pumping, if necessary, a forced diuresis will increase the removal rate. A hemodialysis session of 3 hours can decrease the plasma levels of approximately 50%.
Box with 1 capsule of 150 mg of fluconazole.
Store at room temperature to not more than 30°C and dry.
Keep out of reach of children. Do not take during pregnancy or breastfeeding.
Laboratorios Senosian, S.A. de C.V.